Nemolizumab (Nemluvio, Galderma) is indicated for 'the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy'.
The dosage schedule is available in the summary of product characteristics for nemolizumab.
The list price of nemolizumab is £2,257 per 30‑mg unit (company submission).
The company has a commercial arrangement. This makes nemolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Galderma's webpage on sustainability.